Co-Diagnostics Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los ingresos y los beneficios de Co-Diagnostics disminuyan a un ritmo anual de 86.1% y 5.1% respectivamente, mientras que se espera que el BPA crezca un 8.1% por año.

Información clave

-8.9%

Tasa de crecimiento de los beneficios

7.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	16.0%
Tasa de crecimiento de los ingresos	-97.1%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	12 Aug 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

DB:C97 - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	2	-43	N/A	N/A	1
12/31/2024	4	-38	N/A	N/A	1
6/30/2024	9	-38	-25	-24	N/A
3/31/2024	7	-39	-26	-25	N/A
12/31/2023	7	-35	-23	-22	N/A
9/30/2023	5	-43	-23	-22	N/A
6/30/2023	7	-38	-16	-14	N/A
3/31/2023	12	-32	-8	-7	N/A
12/31/2022	34	-14	5	7	N/A
9/30/2022	53	15	14	15	N/A
6/30/2022	78	28	25	26	N/A
3/31/2022	101	40	36	37	N/A
12/31/2021	98	37	40	41	N/A
9/30/2021	105	42	55	56	N/A
6/30/2021	96	46	52	53	N/A
3/31/2021	93	51	41	42	N/A
12/31/2020	75	42	27	28	N/A
9/30/2020	48	28	6	7	N/A
6/30/2020	26	10	-3	-3	N/A
3/31/2020	2	-6	-6	-5	N/A
12/31/2019	0	-6	-6	-6	N/A
9/30/2019	0	-6	-5	-5	N/A
6/30/2019	0	-6	-5	-5	N/A
3/31/2019	0	-6	-5	-4	N/A
12/31/2018	0	-6	-4	-4	N/A
9/30/2018	0	-6	-4	-4	N/A
6/30/2018	0	-8	-5	-4	N/A
3/31/2018	0	-8	N/A	-4	N/A
12/31/2017	0	-7	N/A	-3	N/A
9/30/2017	0	-6	N/A	-3	N/A
6/30/2017	0	-3	N/A	-2	N/A
3/31/2017	N/A	-2	N/A	-1	N/A
12/31/2016	N/A	-2	N/A	-1	N/A
9/30/2016	0	-2	N/A	-1	N/A
12/31/2015	0	-2	N/A	-2	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que C97 siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que C97 siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que C97 siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos de C97 disminuyan en los próximos 3 años (-86.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos de C97 disminuyan en los próximos 3 años (-86.1% al año).

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de C97 se prevé que sea elevada dentro de 3 años.

Co-Diagnostics Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Co-Diagnostics, Inc. Provides Earnings Guidance for the Third Quarter 2021

Co-Diagnostics, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal 2021

Co-Diagnostics Provides Earnings Guidance for the First Quarter of 2021

Recent updates

Second quarter 2024 earnings released: US$0.25 loss per share (vs US$0.31 loss in 2Q 2023)

Co-Diagnostics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Co-Diagnostics, Inc., Annual General Meeting, Aug 29, 2024

Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform

First quarter 2024 earnings released: US$0.31 loss per share (vs US$0.20 loss in 1Q 2023)

New minor risk - Shareholder dilution

Co-Diagnostics, Inc. to Report Q1, 2024 Results on May 09, 2024

Co-Diagnostics, Inc. Appoints Executive Appointments

Full year 2023 earnings released: US$1.20 loss per share (vs US$0.45 loss in FY 2022)

Co-Diagnostics, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro

Third quarter 2023 earnings released: US$0.20 loss per share (vs US$0.043 loss in 3Q 2022)

Co-Diagnostics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Co-Diagnostics, Inc. Appoints Ivory Chang as Chief Regulatory Affairs Officer

Second quarter 2023 earnings released: US$0.31 loss per share (vs US$0.083 loss in 2Q 2022)

Co-Diagnostics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

New major risk - Share price stability

Co-Diagnostics, Inc., Annual General Meeting, Aug 30, 2023

Co-Diagnostics, Inc. Receives Funding for Co-Dx PCR Home Platform from NIH RADx Tech Program

First quarter 2023 earnings released: US$0.20 loss per share (vs US$0.34 profit in 1Q 2022)

Co-Diagnostics, Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$0.45 loss per share (vs US$1.27 profit in FY 2021)

Third quarter 2022 earnings released: US$0.043 loss per share (vs US$0.40 profit in 3Q 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.043 loss per share (vs US$0.40 profit in 3Q 2021)

Co-Diagnostics, Inc. Appoints Dr. Mark Poritz as New Chief Scientific Officer

Co-Diagnostics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Pomerantz Law Firm Announces the Filing of a Class Action Against Co-Diagnostics, Inc. and Certain Officers

Investor sentiment deteriorated over the past week

Kaplan Fox & Kilsheimer LLP Files Class Action Suit in the United States District Court for the Southern District of New York Against Co-Diagnostics, Inc

Second quarter 2022 earnings released: US$0.083 loss per share (vs US$0.34 profit in 2Q 2021)

Co-Diagnostics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Co-Diagnostics, Inc., Annual General Meeting, Aug 31, 2022

Now 23% undervalued after recent price drop

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Co-Diagnostics, Inc. Completes Principal Design of Test for Monkeypox Virus

Investor sentiment improved over the past week

First quarter 2022 earnings released: EPS: US$0.34 (vs US$0.28 in 1Q 2021)

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

High number of new and inexperienced directors

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Co-Diagnostics, Inc. (NasdaqCM:CODX) completed the acquisition of Advanced Conceptions, Inc.

Co-Diagnostics, Inc. (NasdaqCM:CODX) entered into an Agreement and Plan of Merger to acquire Idaho Molecular Inc.

Third quarter 2021 earnings released: EPS US$0.40 (vs US$0.56 in 3Q 2020)

Co-Diagnostics, Inc. to Introduce at Home/Point of Care Device at AACC on Sept 28

Co-Diagnostics, Inc. SARS-CoV-2 Test Used in New Community Surveillance Method in Italy

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS US$0.34 (vs US$0.54 in 2Q 2020)

Co-Diagnostics, Inc. Provides Earnings Guidance for the Third Quarter 2021

Investor sentiment improved over the past week

Co-Diagnostics, Inc.(NasdaqCM:CODX) dropped from Russell 3000E Index

Co-Diagnostics, Inc Receives CE Marking for Direct Saliva SARS-CoV-2 Test

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS US$0.28 (vs US$0.047 loss in 1Q 2020)

Co-Diagnostics, Inc. Provides Earnings Guidance for the Second Quarter of Fiscal 2021

Investor sentiment deteriorated over the past week

Full year 2020 earnings released: EPS US$1.59 (vs US$0.37 loss in FY 2019)

Co-Diagnostics Provides Earnings Guidance for the First Quarter of 2021

Co-Diagnostics, Inc. to Report Q4, 2020 Results on Mar 25, 2021

Co-Diagnostics, Inc. Announces the Development of A New Point-Of-Care/At Home PCR Diagnostic Testing, Screening and Surveillance Platform

Co-Diagnostics, Inc. Partner to Offer At-Home Saliva Collection Kits for CoPrimer™-Based Covid-19 PCR Test Through Walgreens Find Care®

Investor sentiment deteriorated over the past week

Co-Diagnostics, Inc. Announces CFO Chnages

New 90-day high: €16.20

Investor sentiment improved over the past week

Co-Diagnostics, Inc. Completes FDA EUA Submission for Extraction-Free Saliva COVID-19 Test

Investor sentiment improved over the past week

Independent Director recently sold €104k worth of stock

Investor sentiment improved over the past week